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Abstract 
Background: Depression is highly prevalent in uremic patients undergoing hemodialysis 
(HD). We previously found that low free-carnitine levels are associated with depression 
severity in male patients undergoing HD. However, whether L-carnitine supplementation 
improves the depression state in male patients undergoing HD remains unclear.  
Methods: Sixteen male patients undergoing HD were orally administered 900 mg L-
 3 
carnitine daily or intravenously administered 1000 mg L-carnitine immediately after 
undergoing HD for 3 months. The depression state and various types of carnitine levels 
were evaluated using the self-rating depression scale (SDS) and tandem mass 
spectrometry, respectively, at baseline and 3 months after treatment. 
Results: L-carnitine supplementation significantly increased serum levels of free and 
other acylcarnitine types, associated with improved SDS scores in male patients 
undergoing HD. Univariate analysis revealed that low baseline butyryl- and isovaleryl-
/2-methylbutyryl-carnitine levels were significantly correlated with SDS scores after 
treatment. Multiple regression analysis revealed that butyryl-carnitine levels were a sole 
independent predictor of SDS scores after treatment (r2 = 0.533). 
Conclusion: L-carnitine supplementation for 3 months improved the depression state in 
uremic male patients undergoing HD. Thus, low butyryl-carnitine levels may predict the 
clinical response to L-carnitine supplementation in male patients undergoing HD and who 
have mild depression. 
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1. INTRODUCTION 
Depression, a mood disorder with a high personal, societal, and economic impact, 
is highly prevalent in patients undergoing hemodialysis (HD), possibly accounting for at 
least 20%–30% of patients [1]. Depression is associated with suicide risk and correlated 
with an increased risk for cardiovascular disease in patients with end-stage renal disease 
[2, 3]. Furthermore, in patients undergoing HD, depression may reduce the patient’s 
adherence to medication, thereby negatively affecting the quality of life [4, 5]. Although 
several factors such as malnutrition, inflammation, erythropoietin resistance, 
environmental stress, and atherosclerotic cardiovascular disease contribute to the 
development and progression of depression in uremic patients, the precise underlying 
mechanism of depression and its therapeutic target remain unclear in patients undergoing 
HD [6-9]. 
Carnitine, a natural substance, is supplied by the intake of protein-rich foods and is 
synthesized by the liver, kidney, brain, epididymis, and testis in humans [10, 11]. 
Carnitine plays an important role in fatty acid β-oxidation and energy production by 
transporting long-chain fatty acids from the cytoplasm to the mitochondria as a shuttle 
[11]. We, along with others, reported that serum free-carnitine levels dramatically 
decreased in patients undergoing HD [12, 13]. In addition, we recently found that baseline 
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low free-carnitine levels were independently correlated with the depression severity in 
uremic male patients, as assessed using the self-rating depression scale (SDS), which is a 
widely used questionnaire for evaluating depressive disorders [14]. However, whether L-
carnitine supplementation improves the depression state in patients undergoing HD 
remains unclear. This study aimed to investigate the effects of L-carnithine 
supplementation on SDS scores in uremic male patients undergoing HD.  
 
2. MATERIALS AND METHODS 
2.1. Patients and Protocols 
Sixteen uremic male patients undergoing chronic HD [mean age, 61.4 ± 10.5 years; 
mean duration of HD, 30.2 (1–85) months] and 16 age-matched healthy male controls 
(mean age, 62.1 ± 7.9 years) were enrolled. Patients were dialyzed for 4–5 h with high-
flux dialyzers thrice a week. The patients were orally administered 900 mg L-carnitine 
daily or intravenously administered 1000 mg L-carnitine immediately after undergoing 
an HD session for 3 months. All the patients underwent a complete history, physical 
examination, and blood chemistry analysis such as total, free, and acylcarnitine levels by 
enzymatic methods at baseline and 3 months after the L-carnitine treatment [14]. 
Furthermore, acylcarnitines were profiled using tandem mass spectrometry at baseline 
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and 3 months after the treatment, according to a previously described method [15]. Other 
blood chemistry parameters were measured at a commercial laboratory, as previously 
described (SRL., Inc. Tokyo, Japan) [16]. The depression state was assessed using SDS 
[14]. We were unable to repeatedly evaluate blood chemistry in one patient because of 
severe anemia.  
Informed consent was obtained from all the patients, and the study protocol was 
approved by the Institutional Ethics Committees of Kurume University School of 
Medicine, Japan. This trial was registered with the University Hospital Medical 
Information Network clinical trials database (UMIN000010953). 
 
3. STATISTICAL ANALYSIS 
Data are presented as means ± standard deviation. The presence or absence of 
diabetes mellitus and the use of renin–angiotensin system inhibitors and statins were 
coded as dummy variables. To compare clinical values between healthy controls and 
patients undergoing HD, unpaired t-test was performed. Significant differences of 
variables at baseline and 3 months after the L-carnitine treatment were analyzed using 
paired t-test. Univariate and stepwise regression analyses were also performed to 
determine SDS correlates after the L-carnitine treatment. Statistical significance was 
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defined as p values of <0.05. All statistical analyses were performed using the SPSS 
system ver.20 (Chicago, IL, USA).  
 
4. RESULTS  
4.1. Baseline Clinical Characteristics of Patients Undergoing HD and Healthy 
controls 
 Body mass index, hemoglobin, total protein, serum albumin, alanine 
aminotransferase (ALT), and LDL-cholesterol levels were significantly lower and blood 
urea nitrogen and creatinine levels were higher in patients undergoing HD than in healthy 
controls (Table 1). Baseline total and free-carnitine levels just before the HD session were 
significantly lower and acylcarnitine levels were higher in patients undergoing HD than 
in healthy controls (Figure 1A–C). 
 
4.2. Effects of L-carnitine Supplementation on Clinical Variables, Carnitine Levels, 
and SDS Scores in Patients Undergoing HD 
After the 3-month L-carnitine treatment, serum aspartate aminotransferase, ALT, 
creatinine, and uric acid levels were significantly reduced in patients undergoing HD 
(Table 2). Moreover, the L-carnitine treatment significantly increased total, free, and 
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acylcarnitine levels just before the HD session, which was consistent with decreased SDS 
scores; i.e., the treatment improved the depression state in uremic male patients 
undergoing HD (Figure 2). 
 
4.3. Effects of the L-carnitine Treatment on Serum Levels of Various Types of 
Acylcarnitines and their Associations with SDS Scores 
 To explore which types of carnitines at baseline were correlated with SDS scores 
after the L-cartinine treatment, we further profiled the serum levels of carnitines using 
tandem mass spectrometry. Baseline free-carnitine (C0) and propionyl-carnitine (C3) 
levels just before the HD session were significantly lower and acylcarnitine levels of >3 
carbon atoms, including butyryl-carnitine (C4), isovaleryl-/2-methylbutyryl-carnitine 
(C5), and 3-hydroxyoctadecenoyl-carnitine (C18:1-OH), were higher in patients 
undergoing HD than in healthy controls (Table 3). The L-carnitine treatment for 3 months 
significantly increased all carnitine levels examined, whose levels were reduced after the 
HD session (Table 3). Univariate regression analysis revealed that baseline butyryl-
carnitine and isovaleryl-/2-methylbutyryl-carnitine levels were inversely correlated with 
SDS scores after the L-carnitine treatment (r = -0.730 and p = 0.002 for butyryl-carnitine 
and r = -0.548 and p = 0.034 for isovaleryl-/2-methylbutyryl-carnitine, respectively) 
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(Figure 3). Multiple regression analysis revealed that baseline butyryl-carnitine levels 
were a sole independent predictor of SDS scores after the L-carnitine treatment (r2 = 
0.533). 
 
5. DISCUSSION 
Our analysis demonstrated that (1) serum total and free-carnitine levels just 
before the HD session significantly reduced, whereas acylcarnitine levels increased in 
male patients undergoing HD compared with healthy controls; (2) L-carnitine 
supplementation significantly increased all carnitine levels in patients undergoing HD; 
(3) SDS scores of the patients was significantly reduced after the L-carnitine treatment; 
and (4) although baseline butyryl-carnitine and isovaleryl-/2-methylbutyryl-carnitine 
levels were inversely correlated with SDS scores after the L-carnitine treatment, the 
former was a sole independent predictor of SDS scores in L-carnitine-treated patients 
undergoing HD. 
Depression is one of the most serious complications in uremic patients, possibly 
leading to an increased risk for suicide and reducing the quality of life, even if the patients 
receive conventional anti-depressants [17]. Therefore, the identification of specific 
clinical and biochemical markers, which are associated with the depression state in 
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patients undergoing HD, may provide us with a clue to develop a novel therapeutic 
strategy for the treatment and prevention of depression in uremic patients. Because we 
have previously found that decreased free-carnitine levels are correlated with the 
depression severity, as assessed using SDS, in uremic male patients undergoing HD, we 
specifically examined the effects of L-carnitine supplementation on the depression state 
in such patients. In this study, we found that oral or intravenous administration of L-
carnitine for 3 months significantly increased all carnitine levels, including total, free, and 
acylcarnitines, with various numbers of carbon atoms and improved the depression state 
in patients undergoing HD. These findings have extended our previous observations 
showing an inverse correlation between low serum free-carnitine levels and SDS scores 
in uremic male patients undergoing HD [14], thus suggesting that carnitine deficiency 
represents a therapeutic target for preventing depression in such subjects. A previous 
double-blinded controlled study revealed that treatment with acetylcarnitine (C2), the 
most common acylcarnitine type, has beneficial effects on major depressive disorders in 
elderly patients [18]. Thus, L-carnitine supplementation may ameliorate the depression 
state in patients undergoing HD via various mechanisms, such as improvements in brain 
energy, phospholipid metabolism, and synaptic transmission [18].  
In this study, in contrast to free (C0) and propionyl-carnitine (C3) levels, baseline 
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serum acylcarnitine levels of >3 carbon atoms, such as butyryl-carnitine (C4) and 
isovaleryl-/2-methylbutyryl-carnitine (C5), were significantly increased by two- and 
three-fold in patients undergoing HD compared with healthy controls. Moreover, reduced 
butyryl-carnitine (C4) levels at baseline were found to be a sole independent predictor for 
the depression state, as evaluated using SDS, in L-carnitine-treated patients undergoing 
HD. These observations suggest that long-chain acylcarnitines of >3 carbon atoms can be 
excreted and/or metabolized by the kidney, possibly accounting for increased serum 
acylcarnitine levels in uremic male patients undergoing HD. Because the response of SDS 
scores to the L-carnitine treatment was low in patients undergoing HD with lower baseline 
butyryl-carnitine levels compared with those with higher butyryl-carnitine levels, such a 
small increase in butyryl-carnitine levels observed in patients undergoing HD before the 
L-carnitine treatment may not be enough to improve the depression state. A greater 
increase in serum carnitine levels, via pharmacological L-carnitine supplementation, may 
be needed to ameliorate the depression state in patients undergoing HD. Although we did 
not clarify the exact pathophysiological role of butyryl-carnitine in the depression state 
in uremic male patients undergoing HD, our present observations suggest that baseline 
butyryl-carnitine levels represent a biomarker that could predict reactivity to L-carnitine 
supplementation in such subjects. 
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CONCLUSION 
In conclusion, this study demonstrated that L-carnitine supplementation 
improved the depression state in uremic male patients undergoing HD, thus supporting 
the clinical utility of L-carnitine supplementation in the prevention and treatment of 
depression in such patients. 
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Figure legends 
 
Fig. 1. Total, free, and acylcarnitines in healthy controls and patients undergoing HD.  
 
Fig. 2. SDS scores at baseline and 3 months after the L-carnitine treatment in patients 
undergoing HD.  
 
Fig. 3. Correlation of baseline butyryl-carnitine levels with SDS scores after the L-
carnitine treatment.  
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Table 1. Clinical characteristics of healthy controls and HD patients 
 
     HD patients  Healthy controls p-value 
No. of patients    16  16 
Age (years old)   61.4 ± 10.5 62.1 ± 7.9 0.678 
HD duration (months) (range) 30.2 (1-85) -  - 
HD time/day (hours)  4.3 ± 0.6  -  - 
Body Mass Index (kg/m2)  22.6 ± 3.5 25.5 ± 4.3 0.014 
Systolic blood pressure (mmHg) 148 ± 25  139 ± 20  0.247 
Hemoglobin (g/dL)  11.6 ± 1.1 14.6 ± 1.5 <0.001 
Total protein (g/dL)  6.21 ± 0.55 7.53 ± 0.45 <0.001 
Albumin (g/dL)   3.31 ± 0.44 4.56 ± 0.25 <0.001 
AST (IU/L)   19.6 ± 12.8 27.4 ± 10.2 0.065 
ALT (IU/L)   15.3 ± 8.0 29.4 ± 18.5 0.009 
BUN (mg/dL)   50.2 ± 12.1 18.6 ± 6.3 <0.001 
Serum Cr (mg/dL)  9.10 ± 3.34 0.81 ± 0.11 <0.001 
Uric acid (mg/dL)   6.86 ± 1.01 6.22 ± 1.35 0.203 
Corrected Ca (mg/dL)  9.33 ± 0.43 -  - 
Phosphate (mg/dL)   5.29 ± 1.36 -  - 
Total-cholesterol (mg/dL)  159 ± 27  183 ± 38  0.057 
LDL-cholesterol (mg/dL)  54 ± 22  109 ± 35  0.024 
Triglycerides (mg/dL)   97 ± 46  99 ± 49  0.953 
Diabetes (No.) (-/+)  8/8  16/0  - 
SDS    43.8 ± 7.3 -  - 
Medication 
RAS inhibitors (No.) (-/+) 0/16  16/0  - 
Statins (No.) (-/+)  8/8  16/0  - 
Values are shown as mean±SD or range. No.=number. HD=hemodialysis; AST=aspartate 
aminotransaminase; ALT=alanine aminotransaminase; BUN=blood urea nitrogen; 
Cr=creatinine; Ca=calcium; LDL=low-density lipoprotein; SDS=self-rating depression scale; 
RAS=renin-angiotensin system.  
  
Table 2. Clinical variables at baseline and 3 months after the L-carnitine treatment 
 
                
Variables          Baseline   Post-treatment    p-value  
Hemoglobin (g/dL)       11.6 ± 1.1      11.3 ± 1.3   0.546 
Total protein (g/dL)       6.21 ± 0.55     6.33 ± 0.52   0.125 
Albumin (g/dL)   3.31 ± 0.44     3.31 ± 0.42    1.000 
AST (IU/L)   19.6 ± 12.8     15.2 ± 7.3    0.024 
ALT (IU/L)   15.3 ± 8.0      11.8 ± 4.9     0.024 
BUN (mg/dL)   50.2 ± 12.1     46.3 ± 11.0    0.073 
Serum Cr (mg/dL)   9.10 ± 3.34     8.24 ± 2.67    0.005 
Uric acid (mg/dL)  6.86 ± 1.01     6.33 ± 0.78    0.007 
Corrected Ca (mg/dL)      9.33 ± 0.43     9.09 ± 0.57    0.127 
Phosphate (mg/dL)  5.29 ± 1.36     5.39 ± 1.38    0.818 
Total-cholesterol (mg/dL)   159 ± 27       152 ± 26    0.166 
LDL-cholesterol (mg/dL)   54 ± 22        78 ± 20    0.457 
Triglycerides (mg/dL)     97 ± 46        99 ± 51   0.789 
   
Values are shown as mean ± SD or range. HD=hemodialysis; AST=aspartate aminotransaminase; 
ALT=alanine aminotransaminase; BUN=blood urea nitrogen; Cr=creatinine; Ca=calcium; 
LDL=low-density lipoprotein. 
 
 
        
Table 3. Free and acylcarnitine levels just before and after the HD session in HD patients 
 
Healthy 
controls 
before HD 
baseline 
after HD 
baseline 
before HD 
post-treatment 
after HD 
post-treatment 
C0  43.973±7.581 20.847±7.584*** 7.566±2.720††† 140.843±57.375&&& 40.967±15.719### 
C2  7.695±2.351 7.954±2.148 4.371±0.826††† 
57.977±36.473 
&&& 
18.700±9.866### 
C3 0.409±0.144 0.216±0.124*** 0.041±0.037††† 2.259±1.341&&& 0.540±0.408### 
C4 0.248±0.098 0.440±0.167** 0.141±0.046††† 3.175±2.683&& 0.753±0.690### 
C5:1 0.017±0.003 0.039±0.010*** 0.019±0.004††† 0.075±0.022&&& 0.026±0.007### 
C5 0.103±0.026 0.103±0.034 0.035±0.012††† 0.470±0.236&&& 0.133±0.079### 
C6 0.075±0.020 0.150±0.069** 0.051±0.017††† 0.869±0.772&& 0.222±0.173## 
C5-OH 0.024±0.006 0.068±0.021*** 0.019±0.006††† 0.198±0.131&& 0.049±0.037### 
C8 0.136±0.061 0.209±0.095* 0.057±0.018††† 0.616±0.336&&& 0.182±0.090### 
C10:1 0.156±0.060 0.272±0.114** 0.089±0.029††† 0.629±0.340&& 0.230±0.119### 
C10 0.255±0.120 0.352±0.213 0.096±0.043††† 0.744±0.445&& 0.228±0.145### 
C4DC 0.081±0.024 0.411±0.121*** 0.111±0.030††† 0.721±0.207&&& 0.183±0.061### 
C5DC 0.119±0.044 0.625±0.300*** 0.172±0.066††† 1.717±0.841&&& 0.453±0.254### 
C12 0.067±0.029 0.121±0.049** 0.051±0.019††† 0.204±0.102& 0.112±0.060### 
C14:1 0.083±0.041 0.106±0.053 0.070±0.036† 0.201±0.149& 0.177±0.137 
C14 0.031±0.011 0.125±0.057*** 0.047±0.017††† 0.233±0.179& 0.091±0.059## 
C14-OH 0.015±0.007 0.062±0.050** 0.022±0.012†† 0.127±0.087&& 0.045±0.025### 
C16 0.110±0.022 0.112±0.030 0.106±0.033 0.233±0.130&& 0.200±0.091# 
C16:1-OH 0.008±0.002 0.012±0.004** 0.008±0.003††† 0.022±0.010&& 0.016±0.008## 
C16-OH 0.005±0.001 0.013±0.009** 0.007±0.003†† 0.044±0.079 0.019±0.026 
C18:1 0.131±0.033 0.134±0.040 0.157±0.057 0.266±0.161&& 0.301±0.168 
C18 0.043±0.013 0.040±0.010 0.041±0.010 0.078±0.037&& 0.082±0.037 
C18:1-OH 0.005±0.002 0.007±0.004 0.007±0.003 0.012±0.006&& 0.012±0.007 
C18-OH 0.004±0.001 0.005±0.002* 0.004±0.001†† 0.012±0.012& 0.008±0.004 
Data are expressed as mean±SD. HD=hemodialysis. 
*p<0.05, **p<0.01, ***p<0.001 vs healthy controls; †p<0.05, ††p<0.01, †††p<0.001 vs before HD at 
baseline, &p<0.05, &&p<0.01, &&&p<0.001 vs before HD at baseline, #p<0.05, ##p<0.01, ###p<0.001 
vs before HD at post treatment. 
